TY - JOUR AU - Ilie, Marius AU - Hofman, Paul PY - 2017 TI - Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what’s next? JF - Journal of Thoracic Disease; Vol 9, No 5 (May 28, 2017): Journal of Thoracic Disease Y2 - 2017 KW - N2 - Pembrolizumab ( Keytruda , Merck & Co) is the first immunotherapy to be approved by FDA in the USA and by EMA in Europe for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 expression (tumor proportion score of 50% or above). Up to now, a chemotherapy doublet has been the standard of care for these patients, except in patients with advanced NSCLC harboring targetable genomic alterations such as EGFR mutations or ALK rearrangements. UR - https://jtd.amegroups.org/article/view/13195